| First Author | Ramirez S | Year | 2023 |
| Journal | Int J Mol Sci | Volume | 24 |
| Issue | 23 | PubMed ID | 38069410 |
| Mgi Jnum | J:349667 | Mgi Id | MGI:7566584 |
| Doi | 10.3390/ijms242317087 | Citation | Ramirez S, et al. (2023) Plasma Exchange Reduces Abeta Levels in Plasma and Decreases Amyloid Plaques in the Brain in a Mouse Model of Alzheimer's Disease. Int J Mol Sci 24(23) |
| abstractText | Alzheimer's disease (AD) is the most common type of dementia, characterized by the abnormal accumulation of protein aggregates in the brain, known as neurofibrillary tangles and amyloid-beta (Abeta) plaques. It is believed that an imbalance between cerebral and peripheral pools of Abeta may play a relevant role in the deposition of Abeta aggregates. Therefore, in this study, we aimed to evaluate the effect of the removal of Abeta from blood plasma on the accumulation of amyloid plaques in the brain. We performed monthly plasma exchange with a 5% mouse albumin solution in the APP/PS1 mouse model from 3 to 7 months old. At the endpoint, total Abeta levels were measured in the plasma, and soluble and insoluble brain fractions were analyzed using ELISA. Brains were also analyzed histologically for amyloid plaque burden, plaque size distributions, and gliosis. Our results showed a reduction in the levels of Abeta in the plasma and insoluble brain fractions. Interestingly, histological analysis showed a reduction in thioflavin-S (ThS) and amyloid immunoreactivity in the cortex and hippocampus, accompanied by a change in the size distribution of amyloid plaques, and a reduction in Iba1-positive cells. Our results provide preclinical evidence supporting the relevance of targeting Abeta in the periphery and reinforcing the potential use of plasma exchange as an alternative non-pharmacological strategy for slowing down AD pathogenesis. |
